- Home
- ADM vs PODD Comparison
ADM vs PODD Comparison
Compare ADM & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADM
- PODD
- Stock Information
- Founded
- ADM 1902
- PODD 2000
- Country
- ADM United States
- PODD United States
- Employees
- ADM N/A
- PODD N/A
- Industry
- ADM Packaged Foods
- PODD Medical/Dental Instruments
- Sector
- ADM Consumer Staples
- PODD Health Care
- Exchange
- ADM Nasdaq
- PODD Nasdaq
- Market Cap
- ADM 22.0B
- PODD 19.0B
- IPO Year
- ADM N/A
- PODD 2007
- Fundamental
- Price
- ADM $47.58
- PODD $256.80
- Analyst Decision
- ADM Hold
- PODD Buy
- Analyst Count
- ADM 7
- PODD 17
- Target Price
- ADM $53.57
- PODD $294.65
- AVG Volume (30 Days)
- ADM 6.2M
- PODD 885.5K
- Earning Date
- ADM 04-29-2025
- PODD 05-08-2025
- Dividend Yield
- ADM 4.29%
- PODD N/A
- EPS Growth
- ADM N/A
- PODD 96.55
- EPS
- ADM 3.65
- PODD 5.78
- Revenue
- ADM $85,530,000,000.00
- PODD $2,071,600,000.00
- Revenue This Year
- ADM $4.27
- PODD $20.53
- Revenue Next Year
- ADM $1.57
- PODD $17.42
- P/E Ratio
- ADM $13.03
- PODD $44.40
- Revenue Growth
- ADM N/A
- PODD 22.07
- 52 Week Low
- ADM $44.92
- PODD $160.19
- 52 Week High
- ADM $66.08
- PODD $289.46
- Technical
- Relative Strength Index (RSI)
- ADM 50.15
- PODD 44.00
- Support Level
- ADM $45.49
- PODD $255.75
- Resistance Level
- ADM $48.54
- PODD $270.33
- Average True Range (ATR)
- ADM 1.04
- PODD 8.48
- MACD
- ADM 0.14
- PODD 0.42
- Stochastic Oscillator
- ADM 65.72
- PODD 29.45
About ADM Archer-Daniels-Midland Company
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it world-wide.